Akeso announced a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen. The update is a constructive catalyst for the company’s oncology pipeline, though no efficacy or timeline/financial terms were provided. Net impact is likely limited until clinical readouts emerge.
Akeso announced a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen. The update is a constructive catalyst for the company’s oncology pipeline, though no efficacy or timeline/financial terms were provided. Net impact is likely limited until clinical readouts emerge.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
